Boundless Bio presents findings from preclinical and clinical studies of BBI-355, a novel inhibitor of checkpoint kinase 1 (CHK1), at the AACR Annual Meeting 2024. BBI-355 is being investigated as a potential treatment for oncogene amplified cancers, which are known for their resistance to chemotherapy and targeted therapies.
Studies using preclinical tumor models have demonstrated that BBI-355 overcomes ecDNA-mediated targeted therapy resistance by exploiting the reliance of ecDNA-driven tumor cells on CHK1 for survival. BBI-355 exhibited substantial antitumor activity, including complete and durable regressions, in these models.
Preliminary clinical pharmacodynamic data from the ongoing Phase 1/2 POTENTIATE clinical trial show that BBI-355 is well-tolerated and has the potential to inhibit CHK1 in both skin and tumor tissues. These findings support the continued development of BBI-355 as a differentiated treatment approach for oncogene amplified cancers.
In addition to targeted therapy resistance, research presented at AACR suggests a potential role for ecDNA in acquired resistance to chemotherapy. This finding expands the potential applicability of ecDNA-directed strategies beyond its current focus on targeted therapy resistance.
Boundless Bio remains encouraged by the preclinical and clinical data supporting the development of BBI-355. The ongoing Phase 1/2 POTENTIATE clinical trial will continue to evaluate the safety, efficacy, and tolerability of BBI-355 in patients with oncogene amplified cancers.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
